Trials / Active Not Recruiting
Active Not RecruitingNCT03155061
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Phase 1 Dose Escalating and Expansion Study of ONO-4578 Given as Monotherapy and Combinations of ONO-4578 and ONO-4538 in Subjects With Advanced or Metastatic Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 183 (estimated)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to evaluate the safety, tolerability, pharmacokinetics, efficacy and biomarker of ONO-4578 and combinations of ONO-4578 and ONO-4538 in subjects with advanced or metastatic solid tumors and subjects with unresectable, advanced or recurrent gastric cancer, unresectable, advanced or recurrent colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-4578 | ONO-4578 specified dose on specified days |
| DRUG | ONO-4538 | ONO-4538 specified dose on specified days |
Timeline
- Start date
- 2017-04-19
- Primary completion
- 2027-03-01
- Completion
- 2027-03-01
- First posted
- 2017-05-16
- Last updated
- 2025-06-05
Locations
22 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03155061. Inclusion in this directory is not an endorsement.